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ABSTRACT
Arrhythmogenic cardiomyopathy is a rare genetic disease that is
mostly inherited as an autosomal dominant trait. It is associated
predominantly with mutations in desmosomal genes and is
characterized by the replacement of the ventricular myocardium with
fibrous fatty deposits, arrhythmias and a high risk of sudden death.
In vitro studies have contributed to our understanding of the
pathogenic mechanisms underlying this disease, including its
genetic determinants, as well as its cellular, signaling and molecular
defects. Here, we review what is currently known about the
pathogenesis of arrhythmogenic cardiomyopathy and focus on the in
vitro models that have advanced our understanding of the disease.
Finally, we assess the potential of established and innovative cell
platforms for elucidating unknown aspects of this disease, and for
screening new potential therapeutic agents. This appraisal of in vitro
models of arrhythmogenic cardiomyopathy highlights the discoveries
made about this disease and the uses of these models for future basic
and therapeutic research.
KEY WORDS: Arrhythmogenic cardiomyopathy, ACM, ARVC, Cell
models, In vitro, Molecular mechanisms
Introduction
Arrhythmogenic cardiomyopathy (ACM) is a genetic disease
associated with ventricular arrhythmias and a high risk of sudden
cardiac death (see Box 1 for a glossary of terms). ACM affects
mainly young individuals and trained athletes, and has a worldwide
prevalence ranging from 1:1000 to 1:5000 (Basso et al., 2009).
ACM is characterized by the substitution of the myocardium, the
heart muscle, with fibro-fatty deposits, particularly within the free
wall of the right ventricle (RV) (Fig. 1). This process exacerbates
electric instability and causes impaired ventricular mechanical
function, leading to arrhythmias and progressive heart failure
(Box 1) (Marcus et al., 1982).
ACM is mostly inherited as an autosomal dominant trait and is
characterized by incomplete penetrance and variable expressivity
(Basso et al., 2009). Recessive forms and the contribution of digenic
and compound heterozygosis (Box 1) have also been reported
(McKoy et al., 2000; Norgett et al., 2000; Soveizi et al., 2017;
Xu et al., 2010). Despite genetic heterogeneity, the majority of
genotyped ACM patients harbor mutations in genes that encode
desmosomal proteins (Box 2), including plakoglobin (JUP),
desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2)
and desmocollin-2 (DSC2) (Lazzarini et al., 2015). Mutations in non-
desmosomal genes, including transforming growth factor-β3
(TGFB3), ryanodine receptor 2 (RYR2), transmembrane protein 43
(TMEM43), lamin A/C (LMNA), desmin (DES), titin (TTN),
phospholamban (PLN) and αT-catenin (CTNNA3), are also proposed
to associate with ACM (Lazzarini et al., 2015), although phenotypical
overlap with other cardiomyopathies cannot be excluded.
In the clinic, ACM presents a wide phenotypic spectrum (Box 3).
Despite having genetic bases, ACM is not a congenital disease;
clinical manifestations often develop between the second and fourth
decade of life (Nava et al., 2000). Moreover, despite the autosomal
inheritance, more males are clinically affected than are females
(Corrado and Thiene, 2006; Bauce et al., 2008). Indeed, males show
earlier arrhythmia manifestation (Bhonsale et al., 2013) and more
severe disease expression (Bauce et al., 2008; Marcus et al., 2007,
1982; Blomstrom-Lundqvist et al., 1987; Merner et al., 2008).
Moreover, frequent and competitive exercise increases the risk of
malignant arrhythmias, heart failure and sudden death in ACM
gene-mutation carriers (Corrado et al., 1990).
Lifestyle modifications, anti-arrhythmic drugs, implantable
cardioverter defibrillator (ICD; Box 1) and eventually heart
transplantation are the currently available therapeutic options for
treating ACM. However, to date, a therapy that can tackle the cause
of this disease is not available.
ACM is a relatively newly recognized disease, having only being
described in 1977 as a distinct clinical entity (Fontaine et al., 1977).
Since then, significant advances have been made in understanding
its etiology and pathogenesis, and in diagnosing and managing the
disease. Nevertheless, several biological and clinical features of
ACM remain to be elucidated. Here, we review what is currently
known about the etiology of ACM and its molecular mechanisms,
focusing on in vitro models that are helping researchers unravel the
pathology of this disease and to test hypotheses concerning its
etiology and treatment. To date, a systematic review of ACM cell
models, their strengths and limitations, and the insights into disease
pathogenesis that they have provided, was lacking. For in vivo
model reappraisal, we refer the reader to earlier reviews (McCauley
and Wehrens, 2009; Lodder and Rizzo, 2012; Pilichou et al., 2011).
ACM etiopathogenesis: the theories
The origin of ACM is still largely unknown, but different theories
have been advanced to explain its etiology. In the disontogenic
hypothesis, now abandoned, ACM was believed to be a congenital
defect that arose from abnormal embryonic development of the RV.
This explains why Fontaine and colleagues called the disease
arrhythmogenic right ventricular dysplasia (ARVD) (Fontaine et al.,
1977). Actually, the developmental problems are typical of Uhl’s
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disease, a condition characterized by the complete absence of the
parietal wall of the RV and which has, in the past, been confused
with ACM (Uhl, 1952). Now the two diseases are recognized as
different clinical conditions. Uhl’s disease is usually diagnosed in
neonatal or infant life, whereas ACM patients typically manifest
symptoms from adolescence. Moreover, myocardial fibro-adipose
replacement is not present in Uhl’s anomaly (Pamuru et al., 2010).
Therefore, the term ‘dysplasia’was replaced with ‘cardiomyopathy’
(ARVC), which better describes the disease (Basso et al., 2010).
Since the description of biventricular and left-dominant
forms (Saguner et al., 2014), the name has been updated to
arrhythmogenic cardiomyopathy (ACM).
The inflammatory theory was proposed to address the origin of
the inflammatory cells found in the myocardium of ACM patients. It
is not clear whether the inflammation occurs as a consequence of
cardiomyocyte death or as a primary infective/immune mechanism.
The presence of cardiotropic viruses (e.g. enterovirus and
adenovirus) has indeed been reported in the ACM myocardium
(Bowles et al., 2002). Further studies are needed to unravel the
relevance of inflammation in this disease pathogenesis.
The cardiomyocyte transdifferentiation hypothesis was advanced
to give an explanation of the phenomenon of myocardial
substitution with fibro-fatty deposits (d’Amati et al., 2000). It is
based on the supposition that the cardiomyocytes in ACM hearts
could reprogram and differentiate into adipocytes as a consequence
of the genetic defect. However, it is challenged today because of the
limited evidence of the de-differentiation capabilities of adult
cardiomyocytes.
The dystrophic theory of ACM origin currently prevails because
of the significant similarities of ACM with skeletal muscular
dystrophies (Basso et al., 1996). According to this hypothesis, the
fibro-fatty deposits in ACM myocardium are considered to be scar
tissue that replaces dead cardiomyocytes. In line with this, ACM
mutations cause both cardiomyocyte death, leading to loss of
myocardial tissue, and a signal for aberrant repair (Basso et al.,
2012), as described further below.
Molecular mechanisms of ACM pathogenesis
Much basic and translational research activity has been devoted to
understanding the mechanisms that underpin ACM pathogenesis
Box 1. Glossary
Aneurismal dilation: distention of the ventricular wall, interfering with correct myocardium contractility.
Area composita: cardiac mixed-type junction composed of both desmosomal and adherens junctional proteins.
Auricle: small conical pouch projecting from the upper anterior portion of each atrium.
Brugada syndrome: a genetic diseasemainly caused by mutations affecting sodium channels that lead to a reduced flow of sodium ions (Na+) into cardiac
cells, which alters beating of the heart. It is characterized by ECG alterations and an increased risk of sudden cardiac death.
Cardiac excitation–contraction coupling: sequence of reactions, starting from electrical impulse, which drives intracellular calcium release; calcium
binds troponin and activates muscle contraction.
Current density of channels: the amount of current passing through a cross-sectional area of a conductor in a specific time window.
Digenic/compound heterozygosis: co-inheritance of disease alleles of different genes (digenic) or of the same gene (compound).
ECG: electrocardiogram; the graphic reproduction of electrical activity of the heart, recorded from the body surface. The ECG trace is composed of different
traits, named waves:
• P wave: wave corresponding to the depolarization of the atria.
• QRS complex: the series of waves representing ventricular depolarization (Q: septum; R: left ventricle apex; S: basal and rear regions of left
ventricle). The complex duration is between 60 and 90 ms.
• ε wave: a small positive deflection buried in the end of the QRS complex. It represents delayed activation of affected areas of the right ventricle.
• T wave: corresponds to the repolarization of the ventricles.
Heart failure: a broad spectrum of heart impairments, leading to less-efficient blood pumping.
Hippo pathway: signaling pathway involved in the regulation of cellular proliferation, apoptosis and self-renewal. The core Hippo pathway consists of a
kinase cascade leading to the inhibition of nuclear translocation of twomain transcriptional factors, YAPand TAZ. In ACM, Hippo kinases are activated, YAP
is phosphorylated and its canonical transcriptional activity inhibited.
Implantable cardiac defibrillator (ICD): device to perform cardioversion/defibrillation in the case of ventricular tachycardia, which could otherwise
possibly lead to ventricular fibrillation and sudden death.
Intercalated disc: specialized intercellular cardiomyocyte area providing structural and functional connection between adjacent cardiomyocytes. It
includes gap junctions, fascia adherens, desmosomes, ion channels and mechanoreceptors.
Left/right bundle branch block: pathological condition in which a delay or obstruction occurs along the conduction paths of electrical impulses to the left or
the right cardiac ventricle, respectively.
Lipothymia: fainting or a feeling of faintness.
Long QT syndrome: a rare congenital disorder of delayed repolarization of the heart (prolongation of the QT interval on ECG), leading to a higher risk of
ventricular arrhythmias, ventricular fibrillation and sudden death.
Myocardial remodeling: alteration in the structure (dimensions, mass, shape) of the heart. Specifically, in ACM the main features are fibrous and fatty
deposits in the ventricular myocardium, with thinning of the free walls and segmental or diffuse atrophy.
Palpitation: perception of rapid and/or irregular heartbeats.
Second heart field: area of multipotent progenitor cells contributing to myocardium formation during heart development.
Sudden cardiac death: unexpected natural death owing to cardiac arrest, heralded by abrupt loss of consciousness within 1 hour of the onset of acute
symptoms.
Syncope: partial or complete loss of consciousness due to a temporary reduction in blood flow and shortage of oxygen to the brain.
Ventricular arrhythmias: abnormal rapid heart rhythms originating from the ventricles.
Wallmotion abnormalities: abnormal motion of a region of the heart muscle, causing heart dysfunction. It can be reduced (hypokinesia), absent (akinesia)
or increased (hyperkinesia).
Wnt pathway: signaling pathway involved in various cellular process, such as adhesion, self-renewal, differentiation, migration and proliferation. Wnt
proteins are glycoproteins that act as ligands of Frizzled receptors. The active pathway is characterized by the inhibition of glycogen synthase kinase 3,
which allows the translocation of cytosolic β-catenin into the nucleus and the subsequent transcription of specific genes. In ACM, plakoglobin is thought to
compete with β-catenin, activating adipogenesis, fibrosis and apoptosis.
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Fig. 1. Pathogenic cardiac changes in ACM. (A,B) Representative images of key phenotypic features in human ACM. (A) Hematoxylin–eosin staining of the right
ventricle (RV) in an ACM patient’s heart shows fat deposits (white areas) and disarrayed cardiomyocyte architecture with fibro-fatty infiltrations (asterisk). (B) An
electrocardiogram trace (12 leads, listed on the left-hand side, representing the electrical activity from electrodes on the body surface) of a typical RV arrhythmia,
which commonly occurs in ACM patients. (C-E) Representative light microscopy images of ACM in vitro models and studies of fat accumulation and arrhythmias.
(C) Oil Red O staining of isolated cardiac mesenchymal stromal cells (C-MSCs) from an ACM patient and control highlights the typical lipid accumulation seen
inACM.Lipid accumulation ismeasured byevaluation of red areas into the cell lipid droplets. (D)Depiction ofmurineHL-1 cells, which can be used to generate in vitro
models for electrophysiological studies of the sodium channel Nav1.5 in ACM. (E) The main graph depicts, on the y-axis, the average peak of sodium current (INa)
density [measured in picoamperes/picofarad (pA/pF)] and, on the x-axis, voltage max [Vm; measured in millivolt (mV)] in wild-type (WT) HL-1 cells (black trace),
HL1 cells treated with PKP2-silencing construct (PKP2-KD; red trace) and HL-1 cells treated with a non-silencing construct (PKP2-φKD; blue trace). The
corresponding dot plot, in the inset, shows that silencing PKP2 in HL-1 cells (PKP2-KD) leads to a statistically significant (**P<0.005) decrease in sodium current
density (INa) (see main text for a discussion of the effect of PKP2 loss on sodium current). Adapted with permission from Cerrone et al., 2014. This image (E) is
not published under the terms of theCC-BY licence of this article. Promotional and commercial use of thematerial in print, digital ormobile device format is prohibited
without permission from the publisher Wolters Kluwer. Please contact healthpermissions@wolterskluwer.com for further information. Scale bars: 100 μm.
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(Fig. 1). This research has focused in particular on downstream
alterations provoked by causative gene defects. Mutations in the
ACM-associated genes that encode desmosomal proteins cause
cardiomyocyte connections to be abnormal in shape and
composition, and they also cause altered signaling in all the cell
types that express the mutated genes (Al-Jassar et al., 2011;
Grossmann et al., 2004; Pieperhoff et al., 2008; Bass-Zubek et al.,
2009). Importantly, canonical Wnt and Hippo pathways (Box 1)
have been recognized to be affected by these desmosomal mutations
(Chen et al., 2014).
TheWnt pathway participates in the developmental process during
embryogenesis and is implicated in adult tissue homeostasis. In the
presence of an active canonical Wnt pathway, β-catenin degradation
is inhibited; thus, this protein accumulates in the cytoplasm,
translocates into the nucleus and interacts with T-cell factor/
lymphoid enhancer factor (TCF/LEF) transcription factors,
inducing proliferation and cell fate specification, including
cardiomyocyte differentiation (Li et al., 2011). In ACM, the altered
metabolism of plakoglobin (PG), a desmosome protein that has a high
degree of homology with β-catenin, is thought to be central to disease
pathogenesis. In patients with the disease, PG is abnormally found in
the nuclear compartment (Garcia-Gras et al., 2006; Sommariva et al.,
2016), where it is thought to compete with β-catenin, exerting a
detrimental effect on Wnt signaling and ultimately activating
adipogenesis, fibrosis and apoptosis (Garcia-Gras et al., 2006).
The Hippo pathway, which responds to cell polarity, diffusible
sensing signals and mechanosensing, and which functions to regulate
cell proliferation, apoptosis and cell fate, has been also linked to
ACM. Yes-associated protein (YAP), the Hippo pathway effector, is
phosphorylated in ACM by the Hippo kinase signaling cascade; this
phosphorylation inhibits YAP canonical transcriptional activity and
consequently limits cellular proliferation. Moreover, YAP interaction
with β-catenin further prevents nuclear localization of the latter,
inhibiting Wnt and increasing adipogenesis (Chen et al., 2014).
Aprimarilyelectrical pathogenicmechanism forACMhas also been
proposed. A link between PKP2 and the gap-junction protein connexin
43 (Cx43; encoded by the geneGJA1) has been demonstrated (Oxford
et al., 2007) based on their coexistence in the same macromolecular
complex. This interaction network (‘connexome’) was extended in
2014 to include the voltage-gated sodium channel Nav1.5 (Agullo-
Pascual et al., 2014a). The electric current passing through this channel
is reduced in cardiac myocytes lacking PKP2 (Sato et al., 2009). The
localization of Nav1.5 to cell membranes is Cx43-dependent (Agullo-
Pascual et al., 2014b); thus, functionally, Cx43 reduction parallels with
Nav1.5 reduction (Jansen et al., 2012; Cerrone and Delmar, 2014).
Moreover, the loss of PKP2 stimulates Cx43 complex remodeling,
which results in altered intercalated disc (Box 1) structures (Oxford
et al., 2007). The loss of PKP2 has been associated with Nav1.5
reduced functionality, both in PKP2 heterozygous knockout mice
(Cerrone et al., 2012) and in Brugada syndrome patients (Box 1), who
carry a PKP2 mutation (Cerrone et al., 2014). Interestingly, the
implication of the sodiumchannel inACMpathogenesis linksBrugada
syndromewith ACM; these disorders are already known to share some
clinical features, such as RV arrhythmias and sudden death. Of note, a
minor structural and functional impairment of the RV, mainly in the
RV outflow tract, might also occur in Brugada patients (Pérez Riera
et al., 2005; Böhm et al., 2007).
ACM-related mutations are also found in the gene encoding
RYR2, a calcium release channel (Tiso et al., 2001), and in the PLN
Box 2. Desmosome
Desmosomes (pictured below) are intercellular junctions that provide
strong adhesion between cells. They contain three major components:
desmoplakin, which binds cytoskeleton intermediate filaments,
transmembrane proteins (desmocollin 2 and desmoglein 2), and
armadillo proteins (plakoglobin and plakophilin 2), which mediate the
interactions between transmembrane proteins and desmoplakin. In the
heart, this protein network gives mechanical strength, providing stability
and integrity to the cardiac structure, contributes to tissue
morphogenesis and development, and it also plays an important role in
regulating crucial aspects of cell behavior, such as cell proliferation and
differentiation.
Desmocollin 2
Desmoglein 2Plakoglobin
Plakophilin 2
Desmoplakin
Intercellular 
space
Intermediate
filaments 
Key
Box 3. Clinical features of ACM
ACM is broadly characterized by the presence of fibro-fatty deposits in
the myocardium and by arrhythmia, although it is a phenotypically
heterogeneous condition (Corrado et al., 1997). About 50% of patients
show malignant ventricular arrhythmias at onset, with palpitations,
lipothymias and syncopes. The frequency of ventricular arrhythmias
commonly correlates with the severity of myocardial alterations (Hulot
et al., 2004; Pinamonti et al., 2011). Notably, ventricular arrhythmias are
often elicited by physical activity, during sympathetic nervous system
activation (Wichter et al., 2000). On assessment by electrocardiogram
(ECG), arrhythmias show a left bundle branch block with superior axis
morphology, owing to their origin from the cardiac area called ‘ACM
triangle’ (RV inflow tract, outflow tract, apex) (Marcus et al., 2010). In rare
cases, mostly in the presence of mutations in theDSP andDSC2 genes,
a predominant left ventricular (LV) degeneration (Navarro-Manchon
et al., 2011; Sen-Chowdhry et al., 2008; Bauce et al., 2010) is present,
with right-bundle-branch-block-associated ventricular arrhythmias
(Romero et al., 2013).
Commonly, sudden cardiac death occurs as first manifestation of the
disease, even without overt cardiac structural abnormalities (Sen-
Chowdhry et al., 2005). Conversely, in asymptomatic patients, ACM is
suspected if particular ECG abnormalities are seen, such as T-wave
inversion, QRS duration above 110ms, prolonged rise of S wave and the
presence of an ε wave (Iyer and Chin, 2013). To prevent sudden death
due to ventricular arrhythmias, often an ICD is implanted.
As the disease worsens, cardiac structural alterations appear caused
by a progressive replacement of the RV myocardium with fibro-adipose
tissue, starting from the epicardium and extending transmurally to the
endocardium and commonly diffusing into the LV. This myocardial
atrophy causes aneurysmal dilation and wall motion abnormalities and
leads, in advanced stages, to right- or bi-ventricular severe heart failure
(Corrado et al., 1997; Romero et al., 2013) and eventually to heart
transplant (Corrado et al., 2015). The fibro-adipose replacement creates
areas of electrically inert tissue, which interferes with electrical impulse
conduction and contributes to the typical ECG features and to the
malignant arrhythmias of the disease. This fibro-adipose replacement of
myocardial tissue is considered the hallmark of ACM when associated
with myocyte degeneration and inflammation (Burke et al., 1998). See
the Glossary (Box 1) for definitions of clinical terms used in this Box.
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gene, which encodes for a membrane protein that regulates the Ca2+
pump in cardiac muscle cells (van der Zwaag et al., 2012). This
implies that deficient excitation–contraction coupling (Box 1) might
contribute to ACM. It has been hypothesized that modifications of
intracellular calcium homeostasis contribute to the pathogenesis of
ACM by inducing cellular injury, triggering both apoptosis and
electrical instability (van der Zwaag et al., 2012; Tiso et al., 2001).
ACM associated with mutation of TMEM43, a transmembrane
protein, seems to be mechanistically similar to desmosome-linked
ACM, because TMEM43mutations lead to PG redistribution, altered
Cx43 phosphorylation and function, and impaired conduction
velocity (Merner et al., 2008; Siragam et al., 2014). Similar
observations have been made by analyzing the effect of DES
mutations;DES encodes desmin, an intermediate filament protein that
interactswithDSP. Thesemutations affect the localization ofDSPand
PKP2 at the intercalated discs (Otten et al., 2010). Of note, mutations
in theCTNNA3 gene (van Hengel et al., 2013), which encodes for the
area composita (Box 1) protein αT-catenin, are thought to alter the
homodimeric interactions of the protein or its interactions with
β-catenin. These data, together with the newest finding ofmutations in
the CDH2 gene (Turkowski et al., 2017), coding for N-cadherin,
suggest that ACM could be reconsidered to be a disease affecting the
area composita rather than a purely desmosomal disease.
The association of ACM with mutations of TGFB3 has been
reported (Beffagna et al., 2005). Although a direct causative role has
not been proven, this association could consolidate the link between
ACM and fibrosis. TGFB3 encodes for a cytokine that stimulates
fibrosis by promoting the expression of extracellular matrix genes
and by modulating cell adhesion and the expression of desmosomal
genes in different cell types (Kapoun et al., 2004; Yoshida et al.,
1992).
Finally, ACM has been linked to mutations in genes coding for
the structural proteins titin (stabilizes the sarcomere) and lamin A/C
(provides a nuclear-envelope framework and interacts with
chromatin), although overlap syndromes cannot be excluded.
These mutations lead to an impaired cellular structural stability
and a higher protein turnover (Taylor et al., 2011; Forleo et al.,
2015), provoking cell death and myocardial remodeling (Box 1).
Different in vitro models have helped to define the ACM cellular
phenotype and to investigate these disease mechanisms.
Overview of cellular models of ACM
In this section and in Fig. 2 and Table 1, we give an overview of the
in vitro models of ACM studied to date. These cell models have
contributed to the current understanding of the ACM pathogenic
mechanisms explained above. In vitro models investigated so far
have been derived from the cardiac contractile compartment,
progenitor cells, the stromal compartment and non-cardiac cells.
Cardiomyocytes
Intercalated discs are intercellular specialized areas at the end of
cardiomyocytes that enable cardiac muscles to contract in a
synchronized manner. They are composed of different kinds of
junctions that are essential for myocardial mechanical continuity
(via desmosomes), electrical coupling (via gap junctions) and
electrical activity (via voltage-gated ion channels) between adjacent
cells and, hence, for maintaining correct heart function. In light of
the important functions of intercalated discs, cardiomyocytes have
been proposed to be the pivotal cellular model in ACM. Adult
human cardiomyocytes are, however, difficult to obtain and to
maintain in culture; therefore, various surrogates have been used, as
we describe below.
HL-1 cell line
The HL-1 cell line was obtained with the immortalization of AT-1
atrial cardiomyocytes, isolated from transgenic mice in which
expression of the SV40 large T antigen was controlled by the atrial
natriuretic factor promoter (Field, 1988). This line was the first
cellular model introduced to mimic cardiomyocyte performance
in ACM. HL-1 cells contract even after serial passaging, and
retain differentiated cardiac morphological, biochemical and
electrophysiological properties (Claycomb et al., 1998).
By silencing DSP through stable transfection, using siRNA in
HL-1 cells, Garcia-Gras et al. demonstrated, for the first time, the
translocation of PG into the nucleus, the suppression of the canonical
Wnt pathway and an increase in the adipogenic gene expression with
a consequent accumulation of lipid droplets (Garcia-Gras et al.,
2006). This led to the hypothesis that desmosomal gene knockdown
(e.g. DSP) might provoke Wnt signaling impairment, possibly
mediated by PG. By knocking down PKP2 in HL-1 cells, Hippo
pathway dysregulation was revealed both at the transcript and protein
levels, indicating Hippo pathway involvement in ACM pathogenesis
(Chen et al., 2014).
The impairment of gap junctions and its effect on electrical
synchrony has been demonstrated with the use of PKP2-deficient
HL-1 myocytes. Consistent with this, Cx43 membrane localization
and expression is impaired in these cells (Fidler et al., 2009). A
reduced current amplitude of the Nav1.5 sodium channel has also
been reported in PKP2-deficient HL-1 cells (Cerrone et al., 2014).
Wang et al. (2015) recently demonstrated that an increased activity
of RhoA can influence Cx43 expression in ACM, providing a
potential mechanism to link PKP2 deficiency to Cx43 remodeling.
In addition to PKP2, DSP has also been shown to play an important
role in the stability and signaling of the connexome (Zhang et al.,
2013). Overall, these findings tell us that mutations in different
desmosomal genes result in common impairment of electrical
continuity, supporting the theory that this is a direct cause of
arrhythmias in ACM.
Studies in HL-1 cells have also helped to link non-desmosomal
gene mutations to arrhythmias. A TMEM43 mutation was found to
cause a redistribution of junctional PG and αT-catenin, Cx43
phosphorylation, and altered conduction velocity (Siragam et al.,
2014). Another study provided support for the important role of
RYR2. Specifically, George et al. (2003) transfected HL-1
cardiomyocytes with a RYR2 mutated plasmid and reported higher
levels of calcium release after stimulation; this affected both the
contractile behavior of these cells – possibly leading to the ACM
phenotype of cardiac failure – and the cellular repolarization level,
thus contributing to the arrhythmic phenotype.
The impact of newly discovered ACM-linked mutations has also
been studied in HL-1 cardiomyocytes through the overexpression of
the mutated genes. For example, DSC2 mutations have been studied
to define their pathogenicity and evaluate their effect on localization
of the mutated protein (Beffagna et al., 2007; De Bortoli et al., 2010;
Gehmlich et al., 2011). A PKP2 missense mutation was shown to
generate an unstable PKP2 protein that was incapable of interacting
with DSP and was degraded (Kirchner et al., 2012). DSG2mutations
resulted in a reduced strength of cell–cell contact, demonstrating that
DSG2 is crucial for cardiomyocyte cohesion (Schlipp et al., 2014).
LMNA mutations in HL-1 cells lead to altered nuclear shape and
pore organization, which decrease cardiomyocyte adaptation to
mechanical stress (Forleo et al., 2015). Interestingly, a role for the
inhibitor of apoptosis-stimulating protein of p53 (iASPP) in
maintaining the integrity of desmosomes through its interaction
with DSP and DES has been modeled in HL-1 cells (Notari et al.,
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2015). This finding expands the causes of ACM to the regulators of
desmosomes as well as desmosomal proteins themselves. Moreover,
studies in HL-1 cells were the first to demonstrate the involvement of
αT-catenin in ACM (van Hengel et al., 2013), therefore extending the
junctional defects of ACM to the area composita.
It is important, however, to highlight that the HL-1 line has some
notable shortcomings. First, its mouse origins pose a limitation for
human disease modeling. Second, HL-1 cells are of atrial derivation,
and show an ultrastructure organization that is typical of embryonic
atrial cardiac muscle cells, with poorly organized parallel arrays of
myofibrils; thus, these cells do not fully recapitulate ventricular
cardiomyocytes. This is probably the reason why HL-1 cells are
rarely used for electrophysiological studies.
Cardiomyocytes from animal models
Both neonatal (to guarantee longer survival in culture) and adult
(to better recapitulate adult onset) cardiomyocytes from animal
models have been used in ACM research. Two common
approaches involve transfecting the cardiomyocytes of wild-type
(WT) animals ex vivo with ACM-causing mutations or using
cardiomyocytes from transgenic animals that carry an ACM-
associated mutation.
Consistent with evidence from HL-1 cells, PKP2 silencing in
neonatal rat cardiomyocytes has demonstrated that PKP2 loss causes
altered Cx43 levels and distribution (Oxford et al., 2007). In 2009, the
same group used PKP2-silenced rat cardiomyocytes to show that
PKP2 deficiency affects propagation properties in cardiomyocytes
and alters sodium current function (Sato et al., 2009).
WT neonatal rat cardiomyocytes have also been transfected with
expression vectors that contain mutations in other genes linked to
ACM, including DSC2 (Beffagna et al., 2007) and CTNNA3 (van
Hengel et al., 2013), and these studies have demonstrated their
causative roles in the disease.
Cardiomyocytes from PG-knockout mice, studied in parallel with
those from a double PG/β-catenin knockout, revealed that both of
these N-cadherin binding partners are essential for maintaining
intercalated disc structure and for mechano-electrical coupling
(Swope et al., 2012). Electrophysiological studies have been
performed in cardiomyocytes from PKP2 (Cerrone et al., 2012)
and DSP (Gomes et al., 2012) heterozygous knockout mice, and
reported a deficit or unaltered sodium current density (Box 1),
respectively. Although the results with PKP2 heterozygous
knockout mice are in agreement with those obtained in HL-1
cells, the sodium current in DSP-knockout murine cardiomyocytes
did not show the same impairment as seen in DSP-knockdown
HL-1 cells.
Transgenic zebrafish models of ACM have also been used to
isolate cardiomyocytes for in vitro studies. Notably, a transgenic
zebrafish with cardiac-specific expression of mutated PG has been
used for mechanistic studies, revealing that correct trafficking of
intercalated disc proteins is crucial for cardiomyocyte integrity
(Asimaki et al., 2014; Macrae, 2010).
Even if animal-derived cardiomyocytes represent a valuable and
accessible source of functional cells, they suffer the limitation of
their non-human origin. Consequently, insights obtained with these
tools still need to be confirmed in human-derived models.
Cardiomyocytes from induced pluripotent stem cells
Human induced pluripotent stem cells (hiPSCs) represent a tool to
obtain human-derived cardiomyocytes (Brandão et al., 2017) and
so overcome the interspecies issues noted above. The first hiPSC-
derived ACM cardiomyocytes were generated in 2013 using skin
fibroblasts from an ACM patient. These cells showed reduced
PKP2 and PG expression and an increased lipid-droplet
accumulation when cultured in adipogenic differentiation
medium (Ma et al., 2013).
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Fig. 2. Cellular models used for in vitro studies of ACM. A schematic illustration of the cardiac and non-cardiac cell models used to study ACM. The figure
shows information concerning: the species of origin (animal or human), the stage of cell maturity (adult or embryonic/stem cells), the type of studies performed to
date (immunoassays for protein localization, pathway investigation and cellular electrophysiology) and the specific lipid accumulation processes involved
(adipo- or lipogenesis). BMCs, buccal mucosa cells; COS, CV-1 in origin carrying the SV40 genetic material, derived from monkey kidney tissue; FAPs,
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immortalized AT-1 atrial cardiomyocytes; MSCs, mesenchymal stromal cells; ?, not clear from the performed investigations.
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One of the unsolved shortcomings of hiPSC-derived
cardiomyocytes is their fetal-like phenotype (Ma et al., 2013),
which does not fully recapitulate the adult cardiomyocyte. Kim et al.
(2013) partially overcame this issue by inducing an adult-like
metabolism in ACM-hiPSC cardiomyocytes by stimulating fatty-
acid oxidation. Subsequently, desmosomal ultrastructural changes
were studied in cardiomyocytes differentiated from ACM-hiPSCs,
identifying a correlation between the extent of desmosomal
structural abnormalities and predisposition to lipid accumulation
(Caspi et al., 2013).
Table 1. Cell-based studies of specific aspects of arrhythmogenic cardiomyopathy
Aspect of ACM
studied Cell model References Major findings and consistency across cell-based studies
Lipid
accumulation
HL-1 Garcia-Gras et al., 2006 First to link DSP silencing to lipid accumulation
Epicardial cells Matthes et al., 2011 PKP2 silencing increases lipogenesis
c-kit+/Sca1+ cells Lombardi et al., 2011 JUP mutation leads to lipid accumulation
Cardiomyocytes from
hiPSCs
Ma et al., 2013; Caspi
et al., 2013
PKP2 mutation leads to lipid accumulation (consistent with epicardial cell studies)
C-MSCs Sommariva et al., 2016 The source of adipocytes in ACM are C-MSCs
FAPs Lombardi et al., 2016 DSP silencing leads to lipid accumulation (consistent with HL-1 studies)
Wnt pathway HL-1 Garcia-Gras et al., 2006 DSP silencing provokes the suppression of the canonical Wnt pathway
c-kit+/Sca1+ cells Lombardi et al., 2011 JUP mutation provokes the suppression of the canonical Wnt pathway (consistent
with HL-1 studies). Phenotypic amelioration through pharmacological reactivation
of Wnt (BIO)
BMCs Asimaki et al., 2016 Phenotypic amelioration through pharmacological reactivation of Wnt (SB216763;
consistent with c-kit+/Sca1+ cell studies)
C-MSCs Sommariva et al., 2016 Desmosomal mutations provoke the suppression of the canonical Wnt pathway
(consistent with HL-1 and c-kit+/Sca1+ cell studies). Phenotypic amelioration
through pharmacological reactivation of Wnt (BIO; consistent with c-kit+/Sca1+ cell
and BMC studies)
FAPs Lombardi et al., 2016 Desmosomal mutations provoke the suppression of the canonical Wnt pathway
(consistent with HL-1, c-kit+/Sca1+ cell and C-MSC studies). Phenotypic
amelioration through pharmacological reactivation of Wnt (BIO; consistent with
c-kit+/Sca1+ cell, BMC and C-MSC studies)
Hippo pathway HL-1 Chen et al., 2014 Dysregulation of Hippo pathway
Cx43 Cardiomyocytes from
animal models
Oxford et al., 2007 PKP2 silencing provokes decreased Cx43 expression and abnormal localization
Epicardial cells Oxford et al., 2007 PKP2 silencing provokes decreased Cx43 expression and abnormal localization
(consistent with studies in cardiomyocytes from animal models)
HL-1 Fidler et al., 2009
Zhang et al., 2013
Wang et al., 2015
PKP2 silencing provokes decreased Cx43 expression and abnormal localization
(consistent with studies in cardiomyocytes from animal models and in epicardial
cells)
DSP silencing provokes decreased Cx43 expression and abnormal localization
(consistent with studies in cardiomyocytes from animal models and in epicardial
cells)
Increased RhoA activity is linked to Cx43 remodeling
Nav1.5 channel Cardiomyocytes from
animal models
Sato et al., 2009;
Cerrone et al., 2012
Gomes et al., 2012
PKP2 deficiency reduces Nav1.5 current amplitude
DSP deficiency does not alter Nav1.5 current density (differs from HL-1 studies)
HL-1 Zhang et al., 2013
Cerrone et al., 2014
DSP deficiency reduces Nav1.5 current amplitude [consistent with Sato et al. (2009)
study and not with Gomes et al. (2012)]
PKP2 deficiency reduces Nav1.5 current amplitude (consistent with studies in
cardiomyocytes from animal models)
Validation of
mutations
HL-1 George et al., 2003
Beffagna et al., 2007
Kirchner et al., 2012
van Hengel et al., 2013
Schlipp et al., 2014
Siragam et al., 2014
Forleo et al., 2015
Insight into RYR2 mutation
Insight into DSC2 mutation
Insight into PKP2 mutation
Insight into CTNNA3 mutation (area composita involvement)
Insight into TMEM43 mutation
Insight into DSG2 mutation
Insight into LMNA mutation
Cardiomyocytes from
animal models
Beffagna et al., 2007
van Hengel et al., 2013
Insight into DSC2 mutation
Insight into CTNNA3 mutation (area composita involvement)
HEK293T cells Koop et al., 2008
van Hengel et al., 2013
Insight into RYR2 mutation
Insight into CTNNA3 mutation (area composita involvement)
COS cells Gehmlich et al., 2011 Insight into DSC2 mutation
Keratinocytes Rasmussen et al., 2014 Insight into PKP2 and DSG2 mutations
BIO, 6-bromoindirubin-3′-oxime; BMCs, buccal mucosa cells; C-MSCs, cardiac mesenchymal stromal cells; CTNNA3, αT-catenin; Cx43, connexin 43; DSC2,
desmocollin 2; DSG2, desmoglein 2; DSP, desmoplakin; FAPs, fibro-adipocyte progenitors; hiPSCs, human induced pluripotent stem cells; JUP, plakoglobin;
LMNA, lamin A/C; PKP2, plakophilin 2; RYR2, ryanodine receptor 2; TMEM43, transmembrane protein 43.
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Despite well-known technical limitations, including a high
variability among clones obtained from the same donor, the
advantages of hiPSCs as ACM cell models include their human
origin, their potential unlimited availability and their suitability for
high-throughput screening. Moreover, they carry patient genomes,
representing a unique tool for personalized-medicine approaches. It
is also worth noting that, to date, no studies have attempted to use
genome editing to correct ACM-associated mutations in ACM-
hiPSCs, which would provide indisputable proof of phenotype–
genotype coupling.
Progenitor cells
Progenitor cells have been used to model ACM because of their
stem-cell-like multipotency, and their higher adipogenic potential
compared to terminally differentiated cells.
c-kit+/Sca1+ murine cells
c-kit+/Sca1+ murine cells have been used as an ACM cell model.
c-kit+ cells are the first resident stem-cell population identified in the
heart (Beltrami et al., 2003). These cells are self-renewing and
multipotent in vitro, and can repair damaged myocardium (Dey
et al., 2013). They can also accumulate fat upon in vitro adipogenic
stimulation (Gambini et al., 2010). Sca1 identifies a heterogeneous
population of adult cells, including endothelial, stromal and vascular
cell progenitors. Cells expressing Sca1 show typical features of stem
cells, are characterized by cardiogenic potentials (Oh et al., 2003)
and can accumulate fat in vitro (Matsuura et al., 2004). JUP-
overexpressing c-kit+/Sca1+ cells have been obtained from
transgenic mouse hearts and used to show that PG translocation
into the nucleus and the consequent repression ofWnt/β-catenin lead
to adipogenic differentiation (Lombardi et al., 2011). This study, in
accordance with previous findings, helped to demonstrate that PG is
an essential mediator of themyogenesis-to-adipogenesis switch, and
that adipocytes in ACM patients’ hearts originate, at least in part,
from c-kit+/Sca1+ cells (Lombardi et al., 2011). However, this last
finding has been questioned by a recent study that provided evidence
of few c-kit+ cells differentiating in adipocytes in ACM hearts
(Sommariva et al., 2016). Lately, even the cardiomyogenic potential
of c-kit+ cells is a matter of debate (van Berlo et al., 2014).
A key shortcoming of these progenitors is that they are difficult to
obtain by cell sorting, and they represent a very small subpopulation
of cardiac cells. It is also questionable whether they are all resident
cells. Finally, the c-kit+/Sca1+ cells extensively studied were of
mouse origin.
Epicardial cells
Epicardial cells compose the epithelial monolayer surrounding the
heart. They exert both a protective role and a functional role in the
myocardial response to injury. Epithelial cells share a common origin
with second heart field (Box 1) progenitors (Zhou et al., 2008), and
have been used to model ACM. The silencing of PKP2 in epicardial
progenitors from WT neonatal rat hearts causes changes in Cx43
amount and distribution (Oxford et al., 2007). In line with other data,
PKP2 and Cx43 coexist in the same macromolecular complex in
epicardial cells (Oxford et al., 2007). Subsequently, the role of PKP2
in the migration, proliferation and transdifferentiation of cultured
primary epicardial cells was studied, and demonstrated that increased
lipogenesis and myofibroblast differentiation could be related to
PKP2 loss. Therefore, it was theorized that epicardial and epicardial-
derived cells can act as adipocyte progenitors and contribute to
fibrosis (Matthes et al., 2011). Further studies are needed to provide
robust proof of this hypothesis.
Fibro-adipocyte progenitors
Fibro-adipocyte progenitors (FAPs) represent an alternative cellular
source for investigating fat and fibrosis accumulation in ACM
(Lombardi et al., 2016). FAPs are resident skeletal-muscle
progenitor cells, characterized by the platelet-derived growth
factor receptor α (PDGFRα) marker. FAPs seem to be bi-
potential: different subpopulations express fibroblast markers or
adipogenic transcription factors. Using this model, Lombardi et al.
(2016) confirmed that DSP deficiency suppresses Wnt signaling,
and that this effect is ameliorated through Wnt pharmacological
reactivation. Moreover, adipocyte proliferation was excluded in
ACM, in favor of the hypothesis of FAP differentiation through the
activation of adipogenic transcription factors.
Non-cardiac cells
Buccal mucosa cells
Owing to the limited availability of human myocardial samples,
Asimaki et al. (2016) have proposed buccal mucosa cells (BMCs) as
an in vitro model of ACM. BMCs, which are obtained easily from
the inside of the mouth, are epithelial cells; thus, they express gap
junctions and desmosomes, like cardiac cells. The authors studied
the distribution of proteins usually present in intercalated discs (e.g.
PG and Cx43) and found the same altered distribution in ACM-
patient-derived BMCs as in the patient cardiac tissue. They also
showed that Wnt pharmacological reactivation can apparently
restore normal PG and Cx43 localization in ACM cells (Asimaki
et al., 2016). Thus, despite their non-cardiac derivation, these cells
might be an additional useful tool that can be easily obtained from
large numbers of ACM patients at minimal cost to investigate
disease mechanisms and use in drug screening.
Primary keratinocytes
Primary keratinocytes are another easily obtainable adult human-
derived cell type that express high levels of all isoforms of
desmosomal proteins (Gerull, 2014). Rasmussen et al. (2014)
showed that changes in myocardial expression of PKP2 and DSG2
are mirrored by similar changes in keratinocytes (Rasmussen et al.,
2014). These findings suggest that, despite being of non-cardiac
origin, these keratinocytes might represent a new accessible source
of cells to model patient-specific ACM mutations.
HEK293T cells
The HEK293T cell line, originally derived from human embryonic
kidney, has been used to conduct functional tests on a newly
identified ACM-associated genetic mutation in CTNNA3.
Transfection of the mutant gene into this cell line revealed that
the interaction between mutant αT-catenin and β-catenin was
weaker than withWT αT-catenin (van Hengel et al., 2013). This cell
model, which naturally lacks endogenous RYR2 channels, has also
been used to study the effect of two RYR2 mutations on the store-
overload-induced calcium-release activity. This study found that the
combination of the two RYR2 mutations, which affect important
residues for RYR2 tetramer formation and function, caused
significant changes in calcium release activity (Koop et al., 2008).
By identifying the additive effect of the two mutations, this study
revealed the reason why carriers of compound heterozygous
mutations in the RYR2 gene can be affected by ACM.
COS cells
COS cells, immortalized cell lines derived from monkey kidney
tissue, have also been used to investigate functional impairments
caused by ACM-associated mutations. Rajkumar et al. (2012) used
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COS-7 cells to study the localization of WT and mutated TMEM43;
no changewas observed in desmosomal stability or in the localization
of TMEM43 and two of its binding partners, lamin B and emerin, in
the presence of mutated TMEM43 (Rajkumar et al., 2012). Finally,
COS-1 cells have been used to evaluate the role ofDSC2mutations in
causing ACM. An impaired maturation of mutated DSC2 was
observed, along with a reduced binding to PG (Gehmlich et al.,
2011). This finding is in accordance with the reduced localization of
PG at desmosomes in intercalated discs of ACMpatients’ heart tissue,
reported earlier by the same authors (Asimaki et al., 2009). This
model, however, suffers different limitations: not only are these cells
not cardiac, but they are also of animal origin.
Adult cardiac stromal cells
In 2015, we proposed non-contractile cardiac mesenchymal stromal
cells (C-MSCs) as a novel cell model for ACM (Sommariva et al.,
2016). These cells are abundant in the heart and are involved in
maintaining cardiac cell structure and functional homeostasis in
physiological and pathological conditions (Brown et al., 2005). In
2010, C-MSCs were isolated from human adult auricles (Box 1) and
characterized for the first time (Rossini et al., 2010). C-MSCs are
primary cells obtained directly from human cardiac tissue after
enzymatic digestion with collagenase and selection for plastic
adherence, and they express typical mesenchymal markers (CD29,
CD105, CD44, CD90) (Rossini et al., 2010). Like their bone-
marrow counterpart (BM-MSCs), C-MSCs can differentiate in
endothelium, osteocytes and adipocytes (Rossini et al., 2010), and
are more likely than BM-MSCs to express cardiovascular lineage
markers upon cardiogenic stimulus. They can also be easily
amplified and maintained in vitro for many passages. Notably,
C-MSCs carry patient-specific mutations and their genetic
background (Sommariva et al., 2016). We demonstrated, for the
first time, that, in the explanted hearts of ACM patients, C-MSCs are
involved in active adipogenic differentiation (Sommariva et al.,
2016). C-MSCs isolated from patient ventricular biopsies express
desmosomal genes and, when cultured in adipogenic medium, are
more prone to differentiate into adipocytes than are control C-MSCs
(Sommariva et al., 2016). We took advantage of this cell model to
confirm some of the above-mentioned molecular mechanisms of
ACM, such as PG nuclear localization. Moreover, C-MSCs were
used to demonstrate that ACM-specific features are dependent on
PKP2 deficiency and on Wnt pathway mis-regulation (Sommariva
et al., 2016). In conclusion, C-MSCs represent another promising
new cell model for in vitro studies of ACM mechanisms.
Current cell models of ACM: pros and cons
As highlighted in the previous section, different molecular
mechanisms of ACM have been investigated in vitro thanks to the
availability of several cell models. Below, we aim to point out the
‘lights and shadows’ of each cell type, to help guide researchers who
want to focus on a specific aspect of ACM. Each in vitro model
described has intrinsic advantages and disadvantages, depending on
its origin (animal versus human; cardiac versus non-cardiac), its
maturity (embryonal or undifferentiated versus adult or fully
differentiated) and on the cell type (parenchymal versus stromal).
On the basis of these features, and taking together the findings
summarized in Table 1 and Fig. 2, it is possible to choose which
should be the most suitable cell type in which to investigate specific
aspects of ACM.
ACM mouse models do not show the extensive cardiac adipose
deposits typical of ACM patients (Cerrone et al., 2012; Krusche
et al., 2011), and so cell-based models are preferable to investigate
causative pathways linked to lipid metabolism. Adult cells of human
cardiac origin, carrying patient-specific mutations and genetic
backgrounds, represent the best tool for these studies. However,
adult cardiomyocytes are of limited accessibility and must be
obtained by invasive sampling. Moreover, they do not replicate, are
difficult to maintain in culture and impose the constraint of restricted
transdifferentiation potential. Indeed, manifest lipid accumulation
has been reported only in immature cardiomyocyte models, such as
those obtained from hiPSCs, which still possess a residual potency
(Kim et al., 2013). Also, progenitor cells do differentiate easily in
vitro, but this could possibly be related more to their multipotency
than to disease-specific differentiation (Lombardi et al., 2011;
Matthes et al., 2011). To overcome these limitations, C-MSCs
represent the ideal model for studying lipid metabolism, because
they undergo adipogenic differentiation in patient hearts and
maintain the same ability in vitro (Sommariva et al., 2016).
Because electrical activity is restricted to cardiomyocytes, these
provide the only eligible models to investigate gap-junction and ion-
channel localization, and for electrophysiological studies: the
cardiomyocytes can be either primary or immortalized cells
obtained from animal models or from patient hiPSCs. To date,
limited electrophysiological data are available on the latter (Kim
et al., 2013), although hiPSC-derived cardiomyocytes are
potentially the best model to recapitulate the human pathological
scenario, with the limitation of a fetal-like phenotype (meaning that
adult-onset disease cannot be mimicked). Moreover, further studies
on hiPSC-derived cardiomyocytes could help to shed further light
on different currents, including sodium current, which have been
studied in murine-derived cell models, with conflicting results
(Gomes et al., 2012; Zhang et al., 2013).
Despite their non-cardiac derivation, BMCs represent a possible
tool for large population studies because the sampling technique is
not invasive. Other non-cardiac (and easily accessible) cells in
which desmosomes are expressed could eventually be considered in
the future.
Finally, functional validation of mutations often relies on
overexpression of plasmids carrying mutated genes. Undoubtedly, it
is preferable to use patient-derived cells that already carry the desired
mutations, such as primary cells or hiPSC-derived cardiomyocytes.
However, the presence of the patient’s whole genetic background,
including main mutations and modifier variants, might make it
difficult to assign single-variant pathogenicity. To overcome this issue
and to enable a direct comparison between mutated and WT cells, the
more controlled tool of cardiomyocytes from transgenic animals have
been used (Beffagna et al., 2007; van Hengel et al., 2013). The newest
biomolecular techniques, such as CRISPR/Cas9 will now allow direct
correction of mutations in human cells, thus allowing direct
comparison between mutated and corrected cells.
Unanswered questions and future perspectives
Despite the advances made to date, many questions about ACM
pathogenesis remain unanswered, and cell models could help to
shed light on these outstanding questions.
First, the genetic causes of ACM are not yet fully known.
Notably, about 50% of the probands undergoing genetic screening
fail to have a causative mutation in ACM-associated genes (Marcus
et al., 2013). ACM is characterized by high phenotypic variability
and low penetrance, and, in some patients, by compound
heterozygosity (Lazzarini et al., 2015). Moreover, a screening of
ACM-associated genetic variants in a population of healthy
individuals resulted in 18% positivity rate, questioning the
causative role of these variants (Andreasen et al., 2013). This
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evidence indicates that considerable genetic heterogeneity is
involved in ACM and that it might not be a monogenic
Mendelian disorder. Moreover, non-genetic cofactors might also
contribute to ACM pathogenesis, either providing the trigger for
disease development or worsening disease severity. A deeper
understanding of ACM-associated genes and cofactors might help
to unravel the contribution of new pathways, or to refine our
understanding of other known molecular mechanisms. Direct
comparisons of desmosomal versus non-desmosomal gene-
associated mutations are needed in the same cell type to better
understand downstream disease mechanisms. Given the complexity
of ACM genetics, the identification of digenic inheritance (Xu et al.,
2010) and the contribution of modifier alleles (Sen-Chowdhry et al.,
2010), it would be interesting to investigate cell models modified
with more than one ACM-associated mutation. Alternatively,
primary cells, carrying the entire genetic background of an ACM
patient, could be compared with controls in which the disease
variant is selectively corrected. These cells will help to unravel the
specific contribution of what is considered the main causative
mutation, with respect to the pathogenicity of the other variants.
Interestingly, potential mosaicisms or somatic mutations (Lubitz
and Ellinor, 2015) have never been investigated in ACM. Human
cardiac primary cells are suitable for this.
Certain ACM features are difficult to recapitulate in vitro. Specific
studies are needed to understand the causes of adult-onset ACM and
male prevalence. In long QT (Box 1) (Salama and Bett, 2014) and
Brugada (Benito and Berruezo, 2014) syndromes, the steroid profile
is thought to provoke post-puberty cardiac electrical-property
changes. ACM gender differences deserve specific mechanistic
studies using male versus female models or investigations about the
effect of hormones on the ACM cellular phenotypes. In addition, the
reason for the association between intense physical activity and ACM
risk (Saberniak et al., 2014) is not known. It has been hypothesized
that strong mechanical stretch during exercise acts on the RV, leading
to myocardial damage and promoting cardiac remodeling.
Furthermore, intense sport provokes sympathetic stimulation, which
is a known trigger of arrhythmias (Shen and Zipes, 2014). Indeed,
impairment of cardiac sympathetic innervation and a significant
reduction of postsynaptic β-adrenergic density have been described in
ACM patients (Wichter et al., 2000). In this context, it would be
interesting to address the cellular effect of mechanical or chemical
stimulation. Moreover, the preponderance of RV myocardial
remodeling in ACM has not yet been fully explained. A tentative
response to this question has been provided by evidence that the
cellular developmental origin of pre-adipocytes in ACM hearts is the
second heart field (Lombardi et al., 2009; Zhou et al., 2008), which
gives rise to the RV. Alternatively, the physiological difference
between RV and left ventricle (LV) thickness and wall tension might
provoke a different mechanotransduction of ACM signaling (Thiene
and Marcus, 2013). Modeling ACM with RV versus LV cells will
help to reveal area-of-origin-specific mechanisms.
One of the most appealing applications of reliable cell models is
for high-throughput drug screening and/or candidate testing. To
date, a high-throughput screen performed in a zebrafish ACMmodel
has identified the compound SB216763 as a disease phenotype
suppressor (Asimaki et al., 2014). No ACM cell model has hitherto
been used for drug screening. Marian and coworkers tested one
candidate, GSK3β inhibitor 6-bromoindirubin-3′-oxime (BIO), in
c-Kit+/Sca1+ cells isolated from the heart of mice overexpressing
truncated PG and obtainedWnt pathway restoration and phenotypic
rescue (Lombardi et al., 2011). BIO and SB216763 have been
largely used thereafter in ACM cell models to verify Wnt pathway
involvement (Asimaki et al., 2016; Sommariva et al., 2016;
Lombardi et al., 2016; Kim et al., 2013; Caspi et al., 2013;
Hariharan et al., 2014).
The heart is a complex integrated network, composed of
qualitatively and quantitatively different cell types, including,
among others, myocytes, stromal cells, fibroblasts, adipocytes,
smooth muscle cells, endothelial cells and pericytes, which are
finely tuned through direct and paracrine interactions. New
multicellular models will likely be needed to understand the
interplay between the myocyte and non-myocyte compartments
and how they singularly or synergistically contribute to the different
aspects of ACM pathogenesis. Moreover, tissue-engineered scaffolds
that mimic the myocardial three-dimensional structure will help to
create complex cellular models that allow in-depth mechanistic
assessments as well as tissue-level validation of the effect of novel
therapeutic compounds.
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